GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (STU:VM4) » Definitions » Additional Paid-In Capital

Vanda Pharmaceuticals (STU:VM4) Additional Paid-In Capital : €647.5 Mil(As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Additional Paid-In Capital?


Vanda Pharmaceuticals's quarterly additional paid-in capital declined from Sep. 2023 (€653.1 Mil) to Dec. 2023 (€642.2 Mil) but then increased from Dec. 2023 (€642.2 Mil) to Mar. 2024 (€647.5 Mil).

Vanda Pharmaceuticals's annual additional paid-in capital increased from Dec. 2021 (€592.3 Mil) to Dec. 2022 (€647.8 Mil) but then declined from Dec. 2022 (€647.8 Mil) to Dec. 2023 (€642.2 Mil).

Vanda Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Vanda Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Additional Paid-In Capital Chart

Vanda Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 568.18 534.55 592.26 647.81 642.15

Vanda Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 645.01 640.41 653.09 642.15 647.55

Vanda Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Vanda Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Vanda Pharmaceuticals (STU:VM4) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (STU:VM4) » Definitions » Additional Paid-In Capital
Comparable Companies
NKTR VTYX AVIR SLDB QTTB FHTX MRSN XOMA REPL PSTX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
VNDA:USA VM4:Germany
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Website
https://www.vandapharma.com
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.

Vanda Pharmaceuticals (STU:VM4) Headlines

No Headlines